• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Teleflex Incorporated

    3/28/25 4:19:09 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care
    Get the next $TFX alert in real time by email
    DEFA14A 1 ef20045999_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No. )



    Filed by the Registrant ☐        Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐
    Preliminary Proxy Statement

    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐
    Definitive Proxy Statement

    ☒
    Definitive Additional Materials

    ☐
    Soliciting Material Pursuant to §240.14a-12

    Teleflex Incorporated
    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒
    No fee required.

    ☐
    Fee paid previously with preliminary materials.

    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-1.



     Your Vote Counts!  TELEFLEX INCORPORATED  2025 Annual Meeting  Vote by May 08, 2025  11:59 PM ET  You invested in TELEFLEX INCORPORATED and it's time to vote!  You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on May 09, 2025.  Get informed before you vote  View the Annual Report, Notice & Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 27, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings,  you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a  paper or email copy.  Smartphone users  Point your camera here and vote without entering a  number  I  Vote in Person at the Meeting*  May 09, 2025  11:00 AM EDT  Teleflex Incorporated  550 E. Swedesford Rd., Ste. 400  Wayne, PA 19087  *If you choose to vote these shares in person at the meeting, you must request a "legal proxy." To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance. 
     

     1. Election of Directors  Nominees:  1A Candace H. Duncan  OFor  1B  Gretchen R. Haggerty  0For  1C  John C. Heinmiller  0For  1D  Liam J. Kelly  OFor  1E  Stephen K. Klasko  0For  1F  Andrew A. Krakauer  0For  1G  Neena M. Patil  OFor  1H  Stuart A. Randle  0For  11  Jaewon Ryu  0For  2  Approval, on an advisory basis, of named executive officer compensation.  0For  3  Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2025.  OFor  4  Stockholder proposal, if properly presented at the Annual Meeting, regarding continuous holding requirement for calling a special stockholder meeting.  0Against  Vote at www.ProxyVote.com  THIS IS NOT A VOTABLE BALLOT  This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.  TELEFLEX INCORPORATED  2025 Annual Meeting  Vote by May 08, 2025  11:59PMET  Voting Items  Board Recommends  NOTE: Such other business as may properly come before the meeting or any adjournment thereof. 
     

    Get the next $TFX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TFX

    DatePrice TargetRatingAnalyst
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    2/28/2025Outperform → Mkt Perform
    Raymond James
    2/28/2025$255.00 → $140.00Overweight → Neutral
    Piper Sandler
    2/27/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/1/2024$205.00 → $245.00Neutral → Overweight
    Piper Sandler
    12/4/2023$261.00Equal-Weight → Overweight
    Morgan Stanley
    6/21/2023Buy → Hold
    Needham
    More analyst ratings

    $TFX
    SEC Filings

    View All

    SEC Form 10-Q filed by Teleflex Incorporated

    10-Q - TELEFLEX INC (0000096943) (Filer)

    7/31/25 11:05:11 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TELEFLEX INC (0000096943) (Filer)

    7/31/25 7:00:30 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form 11-K filed by Teleflex Incorporated

    11-K - TELEFLEX INC (0000096943) (Filer)

    6/27/25 2:33:24 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy

    Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced Barrigel™ rectal spacer is now available for purchase in Japan, effective immediately following regulatory approval, insurance coverage acceptance and appropriate use criteria issuance by Japanese academic societies. First cases commenced earlier this month following the approval from the Japanese Pharmaceuticals and Medical Devic

    8/19/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces Quarterly Dividend

    WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiolo

    7/31/25 6:45:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook

    WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue of $780.9, up 4.2% compared to the prior year period; up 1.0% on an adjusted constant currency basis  GAAP diluted EPS from continuing operations of $2.77, compared to $1.69 in the prior year period Adjusted diluted EPS from continuing operations of $3.73, compared to $3.42 in the prior year period 2025 guidance summary (inclusive of the recently closed BIOTRONIK Vascular Intervention business) Raising GAAP revenue growth guidance range to 9.00% to 10.00% Raisi

    7/31/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Teleflex downgraded by BofA Securities with a new price target

    BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously

    3/4/25 7:44:32 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Teleflex from Outperform to Sector Perform and set a new price target of $155.00 from $220.00 previously

    2/28/25 7:34:55 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex downgraded by Raymond James

    Raymond James downgraded Teleflex from Outperform to Mkt Perform

    2/28/25 7:34:03 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Randle Stuart A bought $115,860 worth of shares (1,000 units at $115.86), increasing direct ownership by 15% to 7,547 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 6:02:01 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Krakauer Andrew A bought $115,250 worth of shares (1,000 units at $115.25), increasing direct ownership by 16% to 7,192 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:15:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Chairman, President & CEO Kelly Liam bought $172,605 worth of shares (1,500 units at $115.07), increasing direct ownership by 3% to 45,267 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:14:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Leadership Updates

    Live Leadership Updates

    View All

    DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    3/7/25 6:19:00 PM ET
    $ALK
    $AMBC
    $ATI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

    WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des

    2/27/25 6:36:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Financials

    Live finance-specific insights

    View All

    Teleflex Announces Quarterly Dividend

    WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiolo

    7/31/25 6:45:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook

    WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue of $780.9, up 4.2% compared to the prior year period; up 1.0% on an adjusted constant currency basis  GAAP diluted EPS from continuing operations of $2.77, compared to $1.69 in the prior year period Adjusted diluted EPS from continuing operations of $3.73, compared to $3.42 in the prior year period 2025 guidance summary (inclusive of the recently closed BIOTRONIK Vascular Intervention business) Raising GAAP revenue growth guidance range to 9.00% to 10.00% Raisi

    7/31/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces Second Quarter 2025 Earnings Conference Call Information

    WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on July 31, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (al

    7/17/25 6:30:07 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/14/24 1:28:29 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/8/24 10:29:30 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Teleflex Incorporated (Amendment)

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    2/14/24 10:04:36 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Randle Stuart A bought $115,860 worth of shares (1,000 units at $115.86), increasing direct ownership by 15% to 7,547 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 6:02:01 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Krakauer Andrew A bought $115,250 worth of shares (1,000 units at $115.25), increasing direct ownership by 16% to 7,192 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:15:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Chairman, President & CEO Kelly Liam bought $172,605 worth of shares (1,500 units at $115.07), increasing direct ownership by 3% to 45,267 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:14:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care